ABSTRACT: The first crystal structure of a G protein-coupled receptor (GPCR) was that of the bovine rhodopsin, solved in 2000, and is a light receptor within retina rode cells that enables vision by transducing a conformational signal from the light-induced isomerization of retinal covalently bound to the receptor. More than 7 years after this initial discovery and following more than 20 years of technological developments in GPCR expression, stabilization, and crystallography, the high-resolution structure of the adrenaline binding β 2 -adrenergic receptor, a ligand diffusible receptor, was discovered. Since then, high-resolution structures of more than 53 unique GPCRs have been determined leading to a significant improvement in our understanding of the basic mechanisms of ligand-binding and ligand-mediated receptor activation that revolutionized the field of structural molecular pharmacology of GPCRs. Recently, several structures of eight unique lipid-binding receptors, one of the most difficult GPCR families to study, have been reported. This review presents the outstanding structural and pharmacological features that have emerged from these new lipid receptor structures. The impact of these findings goes beyond mechanistic insights, providing evidence of the fundamental role of GPCRs in the physiological integration of the lipid signaling system, and highlighting the importance of sustained research into the structural biology of GPCRs for the development of new therapeutics targeting lipid receptors.
Introduction
G protein-coupled receptors (GPCRs) constitute the largest superfamily of membrane proteins in the human genome. They transduce signals of a large variety of extracellular stimuli such as light, peptides, neurotransmitters, hormones, lipids, and ions, across plasma membranes, and are implicated in the regulation of every physiological system. As a result, they are the target of~35% of currently prescribed drugs. 1, 2 GPCRs can be grouped into five major classes based on their transmembrane domain sequence conservation. Class A GPCRs are by far the most abundant subfamily with 719 out of approximately 800 receptors known to date. 3 The first report of a high-resolution GPCR crystal structure, published in 2000, 4 was the light receptor rhodopsin captured in the inactive dark state and stabilized by a covalently bound 11-cis-retinal. However, an additional 7 years of extensive technological development was required to solve the first structure of a receptor bound to a diffusible ligand, opening up the GPCR structural biology field. [5] [6] [7] [8] Since then, the structures of more than 53 unique receptors have been reported, 46 of which are Class A GPCRs [ Fig. 1(A) ]. However, the structure determination of GPCRs still remains a significant scientific undertaking, requiring 3-4 years of intense laboratory work on each new receptor. At that rate, complete coverage of the subfamily would take over 100 years. 10 Fortunately, even with onlỹ 6% (46 out of 719 receptors) of the Class A receptor structures determined thus far, an unprecedented diversity of ligand-mediated receptor interaction modes and activation mechanisms is being revealed. 8, [10] [11] [12] [13] [14] [15] Topologically, GPCRs are composed of an extracellular N-terminal domain, a seven-transmembrane (7TM) helical domain (helices I-VII), interleaved with three intracellular (ICLs) and three extracellular loops (ECLs), and an intracellular C-terminal domain that often includes an amphiphilic helix running parallel to the plasma membrane [Fig 1(B) ]. GPCRs transduce chemical signals across the cell membrane by binding to extracellular ligands that induce or stabilize specific receptor conformations. These conformations in turn allow intracellular effectors, such as the heterotrimeric G proteins and arrestins, to be engaged at the intracellular side of the receptor where they initiate intracellular signaling cascades, and regulate receptor activity and cellular trafficking 8 (Fig. 2) . The extracellular domains often play a regulatory role in ligand access into the binding pocket, whereas the intracellular domains participate in coupling to various effectors. For most Class A receptors, the orthosteric binding pocket is located on the extracellular side, inside the 7TM bundle. This location allows the ligand (A) (B) Figure 1 . G protein-coupled receptors (GPCR). (A) Coverage of non-olfactory class A GPCRs grouped respective to ligand type. The crystallized receptors are indicated by a red dot. Adapted from GPCRdb. 9 (B) Schematic of the two-dimensional topology of a GPCR consists of seven transmembrane helical domains, an extracellular N-terminus, three extracellular loops (ECLs), three intracellular loops (ICLs), an additional intracellular helical domain that is parallel to the membrane plane followed by an intracellular C-terminus.
to act on residues that could stabilize slightly different transmembrane configurations, especially that of helices VI and VII, yielding to the opening of an intracellular cleft for the engagement of intracellular effectors. The mechanism by which a ligand acts on a receptor and the resulting consequences on the intracellular effector activity is defined by pharmacologists as the efficacy of the ligand. For example, a ligand that stabilizes the receptor in an active state is defined as an agonist, which increases the engagement of effectors and induces a net positive signal in the cell. In contrast, a ligand that stabilizes the receptor in an inactive state is defined as an inverse agonist, which reduces the basal level of signaling in the cell. Finally, a ligand that binds and stabilizes the receptor without impacting the basal level of signaling in the cell is defined as a neutral antagonist. Bioactive lipids have important physiological roles and lipid-binding receptors from the Class A GPCR subfamily are of great therapeutic value [16] [17] [18] [19] [20] [ Fig. 3(A) , and Tables I-III ]. Yet, lipid-binding GPCRs represent some of the most difficult receptors to study experimentally, because the physicochemical properties of the lipids can (i) in some cases, lead to an elevated non-specific ligand binding; (ii) require the use of additive scaffolding adjuvants to deliver the ligand on-target in vitro; and (iii) sometimes require long incubation periods to reach radioligand binding equilibrium because of their inherently long dissociation half-life. Given the more difficult pharmacology associated with this GPCR subfamily, achieving high-resolution structures of lipid of receptors using X-ray crystallography has become an essential complementary approach to better understand their mechanisms of action, while providing medicinal chemists with an important tool to inform design of more diverse ligands. Therefore, here we present the most recent advances in X-ray structural biology of lipid binding Class A GPCRs in order to shed light on bioactive lipids' action on their cognate receptors. (Fig. 4) . Previously, an enclosed orthosteric binding pocket was observed only in the structure of rhodopsin, which has a long hairpin ECL2 covering the entire retinal binding site and forming a tight lid along with an N-terminal hairpin structure that lies on top. 4 Interestingly, similar folding of an extended ECL2 hairpin was also seen in the restrain lymphopoiesis and adaptive immune response. 45 Autotaxin, a secreted lysophospholipase D that synthesizes lysophosphatidic acid (LPA) in exosomes, forms an autotaxin/LPA/exosome delivery system that then merges with membranes of LPA receptor-containing cells to induce LPA receptor signaling. 46, 47 This carrier system has an important role in the physiological integration of LPA receptor signaling regulation, as the inhibition of autotaxin activity by synthetic and natural steroids (like bile salts) is known to negatively affect LPA receptor signaling. 48 Interestingly, autotaxin has also been proposed to deliver LPAs from the extracellular milieu directly to the orthosteric binding site in LPA receptors through a hydrophobic channel on the enzyme. 49 In the context of lipid receptors, the X-ray crystal structures help reveal these key lipid entry mechanisms. The surface representations of the enclosed lipid receptor structures show that there are different access tunnels to the ligand-binding sites, suggesting that ligand entry could occur from the extracellular space for LPA1, CB1, and BLT1 [ Fig. 5(B) ], or directly through the plasma membrane into the TM region [ Fig. 5 (C) ] for S1P1, GPR40, and PAFR.
Overall structures of lipid receptors
Interestingly, although the LPA6 structure did not contain a ligand, analysis shows that a ligand could have open access from either the membrane or extracellular space [ Fig. 5(D) ]. Additionally, no openings to suggest a pathway for ligand entry were revealed in the EP3 structure [ Fig. 5(E) ]. Clearly the significance of the ligand access channel on these receptors and the precise mechanisms of lipid delivery remains a key area for future exploration, and the available X-ray crystal structures of these receptors help provide an important first step toward a broader physiological understanding of the lipid signaling system.
Lipid receptor activating transitions
CB1 is the only lipid receptor that has been determined in the presence of both agonists and antagonists to date, allowing for the analysis of allosteric transitions associated with receptor activation (Table I) . [29] [30] [31] First, the binding pocket of CB1 displays a large induced-fit that accommodates the transition from antagonist to agonist binding [ Fig. 6(A) ]. This transition involves inward movements of helices I and II with respect to the 7TM bundle along with a clockwise rotation of helix II. This movement the largest conformational change seen for an agonist and antagonist pair. 5,50-52 However, despite the modeling of anandamine in the binding pocket of the CB1 agonist-bound structure, the synthetic agonists used to obtain the structure of CB1 are more similar to the phytocannabinoid Δ9-tetrahydrocannabinol than to the human endocannabinoid. A structure of CB1 with the human endocannabinoid is required to confirm that the changes associated with CB1 activation are conserved with endogenous ligands (Fig. 3) . Class A GPCRs contain conserved structural microswitches that are important for the coordination of TM movements upon receptor activation. 12 Interestingly, in the antagonist-bound CB1 structure the position of the conserved toggle switch residue Trp356 6.48 is stabilized by the interaction with Phe200 3.36 [ Fig. 6(B) ]. In the active-state CB1 structure, the agonist and Phe170 Figure 2 ) and β-strand lid in the antagonist-bound state. Receptors are shown as ribbons and ligands as spheres: prostaglandin E2 receptor 3 (EP3) bound to misoprostol (PDB access code 6m9t; white); GPR40 bound to TAK875 (PDB access code 4phu; blue), apo lysophosphatidic acid receptor 6 (LPA6) (PDB access code 5xsz; yellow), leukotriene B4 receptor 1 (BLT1) bound to BIIL260 (PDB access code 5x33; magenta), sphingosine-1-phosphate receptor 1 (S1P1) bound to ML056 (PDB access code 3v2y; green), lysophosphatidic acid receptor 1 (LPA1) bound to ONO9780307 (PDB access code 4z34; purple), platelet-activating factor receptor (PAFR) bound to ABT491 (PDB access code 5zkq; orange), and CB1 bound to AM6538 (PDB access code 5tgz; brown).
very little additional empty space [ Fig. 6(D) ]. Interestingly, long synthetic ligands do not fit in the structure suggesting that an allosteric transition occurs to accommodate their binding. Docking simulation on the EP3 structure using longer agonists provided evidence that Arg333 7.40 , a residue conserved in most prostanoid receptors and co-ordinating the acid moiety of the prostanoid α-chain, moves away to open a ligand tunnel between helices I and VII [ Fig. 6(E) ]. Overall, it is not surprising that substitution of the acid group of small prostanoids by bulkier moieties would induce a transition in the polar region of the binding site, as the acid group coordinates important interactions among ECL2, helices I-II and VII. Although the polar subpocket of EP3's binding site is predicted to have a high degree of plasticity and may accommodate a large variety of chemical entities, the relationship between these transitions and the receptor's activation it is not clear.
Allosteric modulation of lipid receptors
Many allosteric modulators targeting GPCRs have been developed. 56 In γ-linolenic acid, a natural GPR40 ligand 57 [ Fig. 3(A) ].
Despite the fact that orthosteric sites are classically described as inside the 7TM bundle, the inner volume of the first binding site is very small, and it would not fully accommodate a saturated C12-16 or unsaturated C16-18 lipid. In contrast, it has been suggested using molecular modeling of GPR40 that the γ-linolenic acid binds in the second site. 26 However, since the compounds that bind to the second site (Compound 1 and AP8) are positive allosteric modulator agonists (agoPAMs), the location of the orthosteric binding site for native lipid ligands in GPR40 is still unclear. Additionally, the two sites show different efficacies on activation of heterotrimeric G proteins, with Compound 1 in the second site activating Gq and Gs pathways in contrast to TAK-875 in the first site that was reported to activate only the Gq pathway. This difference in heterotrimeric G protein efficacy seems to account for the dual induction of insulin and GLP-1 secretion by Compound 1.
26
There are distinct changes in GPR40 conformation upon binding ligands to either of the two sites. Ligand occupancy in the first site produces a movement of helix III and the folding of part of ECL2 to accommodate binding [ Fig. 7(D) ]. While ligand binding in the second site shifts the upper parts of helices IV and V. The change in helices IV and V is important as it leads to the displacement of the Leu190 5.46 side chain, effectively removing the space constraint for ligand binding [ Fig. 7(E) ]. Moreover, the presence 's induced-fit allows allosteric ligand AP8 to bind the receptor between the helices V and VI on the outer surface of the seven transmembrane bundle facing the lipid bilayer. Binding of AP8 induces the folding of ICL2, probably favoring the engagement of intracellular effectors.
of the ligand induces the folding of ICL2 through the ligand's interaction with Tyr114, a structural change that accounts for the dual efficacy of the second ligand site. 26 Given the importance of ICL2 for effector coupling, the efficacy from the second site occupancy probably occurs through the direct promotion of effector engagement. 50, 58, 59 Other GPCR crystal structures, such as the glucagon receptor 60 and purinergic P2Y1 receptor, 61 also display allosteric binding pockets facing the lipid bilayer. However, GPR40 is the first GPCR that shows a structurally well-defined allosteric binding site facing the lipid bilayer. Since lipids freely diffuse in the membrane, it would not be surprising if some lipid receptors evolved to transduce the signal from a native lipid binding location outside the 7TM bundle. Additional lipid receptor structures are needed to fully understand the action of natural lipids on their receptors.
Future directions and conclusion
Lipid-binding GPCRs play important physiological roles and are important active pharmaceutical targets for the treatment of many pathophysiological conditions (Tables II-III) . The recent emergence of X-ray crystal structures of lipid-binding GPCRs has already provided a new understanding of these lipid's interactions with GPCRs from allosteric modulation to signal transduction (Tables I and II) . A tool, such as X-ray crystallography, that allows the interpretation of the atomic details of lipids' action on their receptor is important, as lipid receptors generally display a more complex pharmacology than receptors of other free-circulating hormones and have an ability to mediate the response from a broader range of ligands. 62 Also, lipids can be metabolized, a process that changes their selectivity for their cognate receptors and their physiological roles. 55, 63 Xray structural biology will play a key role in decoding this process at the receptor level. For example, the fact that the CB1-binding endocannabinoid anandamide can be phosphorylated to switch selectivity toward the LPA1 receptor had been suggested by the analysis of the LPA1 X-ray crystal structure. 25, 55, 63 The data gathered from the few available structures of lipid-binding receptors show that they possess a higher binding site plasticity that allows for the promiscuity of lipid action. A better understanding of such plasticity can be achieved using X-ray crystallography of lipid-binding GPCRs, and would be an essential guide for the design of next generation drugs targeting this GPCR family.
